The short version of GHRH analog fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-20. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Stability testing examines how the molecule changes under controlled stress. Thermal stress, light exposure, and extremes of pH are applied separately so that each degradation route can be attributed to a specific cause. The main observed changes are oxidation, deamidation, and aggregation into dimers or higher-order species. Accelerated studies at elevated temperature are used to estimate behavior over longer periods, though such extrapolation carries uncertainty. For a lyophilized powder, residual moisture and the choice of bulking agent strongly influence how quickly these changes appear.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
In habitual users, however, tolerance develops rapidly; the perceived attention and alertness boost after overnight abstinence primarily reverses mild withdrawal deficits (fatigue, reduced concentration) rather than elevating performance above a true non-dependent baseline, consistent with the withdrawal-reversal hypothesis.
Venlafaxine was originally marketed as Effexor in most of the world; generic venlafaxine has been available since around 2008 and extended-release venlafaxine has been available since around 2010. Venlafaxine is sold under many brand names worldwide. In some countries, Effexor is marketed by Viatris after Upjohn was spun off from Pfizer.
== History == The US Food and Drug Administration (FDA) approved copper histidinate based on evidence from two clinical trials, in which efficacy and safety were evaluated in 66 and 129 participants with Menkes disease, respectively, treated with copper histidinate. The trials were conducted at a single site in the United States. Copper histidinate was evaluated in 129 participants with Menkes disease receiving three years of copper histidinate treatment in two open-label, single-arm clinical trials (trial 1, NCT00001262 and trial 2, NCT00811785). Survival data from participants treated with copper histidinate in these two trials were compared to survival data from an untreated contemporaneous external control cohort as collected under a protocol amendment of trial 2. In both trials, participants aged younger than one year of age received 1.45 mg of copper histidinate given subcutaneously twice a day until they reached one year of age; participants aged one year of age and older received 1.45 mg of copper histidinate subcutaneously once daily for up to three years. Safety data were evaluated in 129 participants receiving copper histidinate in trial 1 and trial 2. There were insufficient safety data in the control group for evaluation.
Fatty acids are an integral part of the phospholipids that make up the bulk of the plasma membranes, or cell membranes, of cells. These phospholipids can be cleaved into diacylglycerol (DAG) and inositol trisphosphate (IP3) through hydrolysis of the phospholipid, phosphatidylinositol 4,5-bisphosphate (PIP2), by the cell membrane bound enzyme phospholipase C (PLC).
Sources: en.wikipedia.org
==== Cyclooxygenases ==== Prostaglandins are produced following the sequential oxygenation of arachidonic acid, DGLA or EPA by cyclooxygenases (COX-1 and COX-2) and terminal prostaglandin syntheses. The classic dogma is as follows:
=== Hypodermis === Beneath these layers lies the hypodermis, which is composed of adipose tissue, fascia, as well as larger lymphatic and blood vessels. For joint and muscle disease treatment, topically applied drugs such as non-steroidal anti-inflammatory drugs (NSAIDs) can penetrate the subcutaneous tissue or even deeper tissues in the hypodermis. Drugs are primarily delivered into the underlying muscle by direct penetration without prior entry into the systemic circulation to prevent unintended side effects.
Like DNA, RNA can store and replicate genetic information. Although RNA is considerably more fragile than DNA, some ancient RNAs may have evolved the ability to methylate other RNAs to protect them. The concurrent formation of all four RNA building blocks further strengthens the hypothesis. Enzymes made of RNA (ribozymes) can catalyze (start or accelerate) chemical reactions that are critical for life, so it is conceivable that in an RNA world, ribozymes might have preceded enzymes made of protein. Many coenzymes that have fundamental roles in cellular life, such as acetyl-CoA, NADH, FADH, and F420, are structurally strikingly similar to RNA and so may be surviving remnants of covalently bound coenzymes in an RNA world. One of the most critical components of cells, the ribosome, is composed primarily of RNA. Although alternative chemical paths to life have been proposed, and RNA-based life may not have been the first life to exist, the RNA world hypothesis seems to be the most favored abiogenesis paradigm. However, even proponents agree that there is still not conclusive evidence to completely falsify other paradigms and hypotheses. Regardless of its plausibility in a prebiotic scenario, the RNA world can serve as a model system for studying the origin of life. If the RNA world existed, it was probably followed by an age characterized by the evolution of ribonucleoproteins (RNP world), which in turn ushered in the era of DNA and longer proteins. DNA has greater stability and durability than RNA, which may explain why it became the predominant information storage molecule.
Amino acids are the precursors to proteins. They join by condensation reactions to form short polymer chains called peptides or longer chains called either polypeptides or proteins. These chains are linear and unbranched, with each amino acid residue within the chain attached to two neighboring amino acids. In nature, the process of making proteins encoded by RNA genetic material is called translation and involves the step-by-step addition of amino acids to a growing protein chain by a ribozyme that is called a ribosome. The order in which the amino acids are added is read through the genetic code from an mRNA template, which is an RNA derived from one of the organism's genes. There are 22 amino acids that get naturally incorporated into polypeptides; these are called proteinogenic amino acids or natural amino acids. Of these, 20 are encoded by the universal genetic code. The remaining 2, selenocysteine and pyrrolysine, are incorporated into proteins by unique synthetic mechanisms. Selenocysteine is incorporated when the mRNA being translated includes a SECIS element, which causes the UGA codon to encode selenocysteine instead of a stop codon. Pyrrolysine is used by some methanogenic archaea in enzymes that they use to produce methane. It is coded for with the codon UAG, which is normally a stop codon in other organisms.
=== Otospondylomegaepiphyseal dysplasia === Approximately 10 mutations identified in the COL11A2 gene are responsible for otospondylomegaepiphyseal dysplasia (OSMED). Most of these mutations result in a complete lack of pro-alpha2(XI) chains, which leads to a loss of function of type XI collagen. Some mutations affect the production of the pro-alpha2(XI) chain and disrupt normal collagen assembly. Because this type of collagen is an important component of cartilage and other connective tissues, these mutations result in the characteristic signs and symptoms of OSMED.
Sources: en.wikipedia.org
If the corneal stroma develops visually significant opacity, irregularity, or edema, a cornea of a deceased donor can be transplanted. Because there are no blood vessels in the cornea, there are also few problems with rejection of the new cornea. When a cornea is needed for transplant, as from an eye bank, the best procedure is to remove the cornea from the eyeball, preventing the cornea from absorbing the aqueous humor. There is a global shortage of corneal donations, severely limiting the availability of corneal transplants across most of the world. A 2016 study found that 12.7 million visually impaired people were in need of a corneal transplant, with only 1 cornea available for every 70 needed. Many countries have years-long waitlists for corneal transplant surgery due to the shortage of donated corneas. Only a handful of countries consistently have a large enough supply of donated corneas to meet local demand without a waitlist, including the United States, Italy, and Sri Lanka.
Later it was shown in ab initio calculations with the high level of accuracy that the Rf atom has the ground state with the 6d2 7s2 valence configuration and the low-lying excited 6d1 7s2 7p1 state with the excitation energy of only 0.3–0.5 eV. In an analogous manner to zirconium and hafnium, rutherfordium is projected to form a very stable, refractory oxide, RfO2. It reacts with halogens to form tetrahalides, RfX4, which hydrolyze on contact with water to form oxyhalides RfOX2. The tetrahalides are volatile solids existing as monomeric tetrahedral molecules in the vapor phase. In the aqueous phase, the Rf4+ ion hydrolyzes less than titanium(IV) and to a similar extent as zirconium and hafnium, resulting in the RfO2+ ion. Treatment of the halides with halide ions promotes the formation of complex ions. The use of chloride and bromide ions produces the hexahalide complexes RfCl2−6 and RfBr2−6. For the fluoride complexes, zirconium and hafnium tend to form hepta- and octa- complexes. Thus, for the larger rutherfordium ion, the complexes RfF2−6, RfF3−7 and RfF4−8 are possible.
With the increase of loneliness in the early 21st century, AI is sometimes identified as a potential source of relief to this problem. It would be possible, via human-like qualities built into AI products, for individuals to assume that this need can be met by artificial means. In some cases, people approach artificial intelligence for companionship when they believe that they would not find acceptance due to feeling outcast. Examples of harm coming to humans from advanced chatbots have been reported in courts in the United States, with AI companies accused of creating products that endanger humans through emotional confusion or deception.
=== REDEFINE 2 === In June 2025, results were published in the New England Journal of Medicine on REDEFINE 2, a 68-week, double-blind, Phase III clinical trial enrolling 1,206 participants. REDEFINE 2 reported that obese or overweight adult patients with type 2 diabetes lost 13.7% of their weight over 68 weeks with Cagrilintide/semaglutide, compared with 3.1% with placebo.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the standard technique for purity and content. Mass spectrometry provides orthogonal confirmation of identity. The two are normally used together rather than in isolation.